Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – What’s Next?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw unusually-high trading volume on Tuesday . Approximately 3,047 shares changed hands during trading, an increase of 92% from the previous session’s volume of 1,589 shares.The stock last traded at $10.17 and had previously closed at $10.1460.

Bavarian Nordic Stock Up 0.2%

The firm has a market capitalization of $2.42 billion, a PE ratio of 6.56 and a beta of 1.36. The firm has a 50-day moving average price of $10.09 and a 200 day moving average price of $11.04.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Friday, November 14th. The company reported $0.72 EPS for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The company had revenue of $281.11 million during the quarter. Equities research analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.